CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons von Tefferi, A, Lasho, T L, Finke, C M, Knudson, R A, Ketterling, R, Hanson, C H, Maffioli, M, Caramazza, D, Passamonti, F, Pardanani, A

Volltext

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms von Pardanani, A, Lasho, T L, Finke, C M, Mai, M, McClure, R F, Tefferi, A

Volltext

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates von Tefferi, A, Levine, R L, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Finke, C M, Mullally, A, Li, C-Y, Pardanani, A, Gilliland, D G

Volltext

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis von Tefferi, A, Pardanani, A, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Gangat, N, Finke, C M, Schwager, S, Mullally, A, Li, C-Y, Hanson, C A, Mesa, R, Bernard, O, Delhommeau, F, Vainchenker, W, Gilliland, D G, Levine, R L

Volltext

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis von Tefferi, A, Lasho, T L, Abdel-Wahab, O, Guglielmelli, P, Patel, J, Caramazza, D, Pieri, L, Finke, C M, Kilpivaara, O, Wadleigh, M, Mai, M, McClure, R F, Gilliland, D G, Levine, R L, Pardanani, A, Vannucchi, A M

Volltext

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F von Tefferi, A, Jimma, T, Sulai, N H, Lasho, T L, Finke, C M, Knudson, R A, McClure, R F, Pardanani, A

Volltext

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients von Lasho, T L, Finke, C M, Hanson, C A, Jimma, T, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

Volltext

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients von Patnaik, M M, Hanson, C A, Hodnefield, J M, Lasho, T L, Finke, C M, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

Volltext

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia von Patnaik, M M, Lasho, T L, Vijayvargiya, P, Finke, C M, Hanson, C A, Ketterling, R P, Gangat, N, Tefferi, A

Volltext

AKT is a therapeutic target in myeloproliferative neoplasms von Khan, I, Huang, Z, Wen, Q, Stankiewicz, M J, Gilles, L, Goldenson, B, Schultz, R, Diebold, L, Gurbuxani, S, Finke, C M, Lasho, T L, Koppikar, P, Pardanani, A, Stein, B, Altman, J K, Levine, R L, Tefferi, A, Crispino, J D

Volltext

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients von Pardanani, A, Guglielmelli, P, Lasho, T L, Pancrazzi, A, Finke, C M, Vannucchi, A M, Tefferi, A

Volltext

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients von Pardanani, A, Lasho, T L, Finke, C M, Gangat, N, Wolanskyj, A P, Hanson, C A, Tefferi, A

Volltext

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations... von Patnaik, M M, Lasho, T L, Finke, C M, Gangat, N, Caramazza, D, Holtan, S G, Pardanani, A, Knudson, R A, Ketterling, R P, Chen, D, Hoyer, J D, Hanson, C A, Tefferi, A

Volltext

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associat... von Tefferi, A, Lasho, T L, Patnaik, M M, Finke, C M, Hussein, K, Hogan, W J, Elliott, M A, Litzow, M R, Hanson, C A, Pardanani, A

Volltext

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients von Patnaik, M M, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Knudson, R A, Ketterling, R P, Tefferi, A, Solary, E

Volltext

IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia von Caramazza, D, Lasho, T L, Finke, C M, Gangat, N, Dingli, D, Knudson, R A, Siragusa, S, Hanson, C A, Pardanani, A, Ketterling, R P, Tefferi, A

Volltext

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes von Patnaik, M M, Padron, E, LaBorde, R R, Lasho, T L, Finke, C M, Hanson, C A, Hodnefield, J M, Knudson, R A, Ketterling, R P, Al-kali, A, Pardanani, A, Ali, N A, Komroji, R S, Tefferi, A

Volltext

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms von Patnaik, M M, Lasho, T L, Finke, C M, Gangat, N, Caramazza, D, Siragusa, S, Hanson, C A, Pardanani, A, Tefferi, A

Volltext

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML von Laborde, R R, Patnaik, M M, Lasho, T L, Finke, C M, Hanson, C A, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

Volltext

U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype von Tefferi, A, Finke, C M, Lasho, T L, Wassie, E A, Knudson, R, Ketterling, R P, Hanson, C A, Pardanani, A

Volltext